{
    "nct_id": "NCT06568939",
    "official_title": "A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Projected life expectancy of at least 12 weeks.\n* Must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory\n* Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.\n* Must have a known epidermal growth factor receptor (EGFR) activating mutation status.\n* Actionable alterations in genes other than EGFR are permitted.\n* Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n* Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.\n* Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Adenosquamous or neuroendocrine histology, or sarcomatoid features.\n* Actionable EGFR activating mutations.\n* Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.\n* Received prior docetaxel therapy.\n* Metastases to the central nervous system (CNS) are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.\n* History of other malignancies except those stated in the protocol.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.\n* Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.\n* Major surgery within 21 days prior to randomization.\n* Clinically significant condition(s) including but not limited to those listed in the protocol.\n* Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.\n* Grade >= 2 edema or lymphedema.\n* Grade >= 2 ascites or pleural effusion.\n* Grade >= 2 neuropathy.\n* Active uncontrolled bacterial or viral infection.\n* Active corneal disorder.",
    "miscellaneous_criteria": ""
}